Ivana Magovčević-Liebisch, Vigil CEO (file photo)

Vig­il Neu­ro­science launch­es with a $50M Se­ries A and two for­mer Am­gen neu­ro­science can­di­dates

Af­ter more than 20 years in the in­dus­try, Ivana Magov­če­vić-Liebisch had done it all — ex­cept build a com­pa­ny from scratch. Then Bruce Booth at At­las Ven­ture men­tioned a cou­ple of TREM2 as­sets he was try­ing to snag from Am­gen’s old neu­ro­science pipeline.

“I came in to help them bring the as­sets in,” Magov­če­vić-Liebisch said. “As we start­ed work­ing to­geth­er, it be­came a clear fit… It kind of checked all the box­es.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.